The value of multimode imaging technology in transcranial magnetic stimulation treatment of Parkinson's disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048386

Enrollment

Unknown

Registered

2021-07-06

Start date

2021-06-30

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Experimental group:According to the multimodal imaging technology accurately guided transcranial magnetic stimulation treatment of the corresponding target area

Eligibility

Sex/Gender

Male

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.PD patients, aged 18 to 75 years, meet the diagnostic criteria of International Dyskinesia Association (MDS) and Parkinson's disease in China; 2.No dementia based on clinical comprehensive assessment, MMSE score (illiterate > 17, primary school >20, junior high school and above > 24); 3.Patients without contraindications to MRI scanning and transcranial magnetic stimulation.

Exclusion criteria

Exclusion criteria: 1.Patients with severe anxiety, depression and other psychiatric symptoms; 2.Patients with a history of severe diabetes, hypertension, cerebrovascular disease and other neurological diseases, obvious brain trauma and neurological surgery.

Design outcomes

Primary

Measure	Time frame
New edition of the World Dyskinesia Society Comprehensive Evaluation Scale for Parkinson's disease;Functional magenetic resonance imaging;	—

Countries

China

Contacts

Public ContactWang Meiyun

He'nan Provincial People's Hospital

mywang@ha.deu.cn+86 13703465381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026